Inovio Pharmaceuticals, Inc.

Equities

INO

US45773H4092

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
13.03 USD +5.25% Intraday chart for Inovio Pharmaceuticals, Inc. +20.76% +112.91%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target MT
Transcript : Inovio Pharmaceuticals, Inc. - Special Call
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment MT
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi) CI
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment MT
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from NASDAQ Biotechnology Index CI
Transcript : Inovio Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Inovio Shares Rise 8% After FDA Feedback for INO-3107 DJ
Inovio Pharmaceuticals Advised to File BLA for Drug Candidate to Treat Recurrent Respiratory Papillomatosis MT
Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107 CI
Inovio Says US FDA Breakthrough Therapy Designation Received for Recurrent Respiratory Papillomatosis Drug Candidate MT
Transcript : Inovio Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Inovio Pharmaceuticals to Cut 30% of Full-Time Workforce MT
Inovio Pharmaceuticals Plans to Cut About 30% of Workforce MT
Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell Microcap Value Index CI
Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell Small Cap Completeness Index CI
Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2500 Index CI
Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 3000 Index CI
Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2000 Index CI
Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 3000E Value Index CI
Chart Inovio Pharmaceuticals, Inc.
More charts
Inovio Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. The Company's lead candidates are focused on diseases associated with HPV. Its DNA medicines pipeline includes INO-3107 for HPV-related Recurrent Respiratory Papillomatosis (RRP), VGX-3100 for the treatment of HPV-related Cervical HSIL, INO-5401 for the treatment of Glioblastoma Multiforme (GBM), INO-5151 (INO-5150 + INO-9012) for the treatment of Prostate Cancer, INO-4800 for COVID-19, INO-4201 for Ebola Virus Disease, INO-4700 for Middle East Respiratory Syndrome (MERS) and INO-4500 for Lassa Fever. Its DNA medicine platform consists of DNA plasmids and its investigational smart device, CELLECTRA, which is used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of three models.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
13.03 USD
Average target price
19.25 USD
Spread / Average Target
+47.74%
Consensus
  1. Stock
  2. Equities
  3. Stock Inovio Pharmaceuticals, Inc. - Nasdaq
  4. News Inovio Pharmaceuticals, Inc.
  5. Maxim Group Adjusts Inovio Pharmaceuticals Price Target to $11 From $20, Maintains Buy Rating